Quarterly ResultMay 26, 2026, 04:13 PM
Apimeds Pharma US Q1 Net Loss $(35.06)M; Going Concern Doubt
AI Summary
Apimeds Pharmaceuticals US, Inc. reported a substantial net loss of $(35.06) million for the first quarter of 2026, a significant increase from the prior year, primarily driven by increased operating expenses including a one-time charge and unrealized losses on digital assets. The company's accumulated deficit has grown to over $45 million, raising substantial doubt about its ability to continue as a going concern. Despite drawing $10.9 million from a PIPE financing, the financial results reflect considerable challenges in both its biopharmaceutical and digital asset segments.
Key Highlights
- Apimeds Pharma US reported a net loss of $(35,059,852) for Q1 2026, significantly up from $(402,397) in Q1 2025.
- The company's accumulated deficit reached $(45,452,913) as of March 31, 2026.
- Cash used in operating activities increased to $(2,067,727) for Q1 2026 from $(20,313) in Q1 2025.
- Total operating expenses surged to $12,185,694 in Q1 2026, including a one-time G&A charge of $8.1 million.
- An unrealized loss of $(22,078,601) from changes in fair value of digital assets was recorded in Q1 2026.
- Total assets decreased to $141,219,157 as of March 31, 2026, from $164,183,736 at December 31, 2025.
- Total current liabilities increased to $14,584,883 as of March 31, 2026, from $10,706,455 at December 31, 2025.
- The company drew $10,900,000 from a PIPE financing, with $8,000,000 recognized as restricted cash.
Price Impact
More from APUS